Innovation in Technology Sparks Growth in Consumer Genomics: North America Leads While Asia-Pacific Gears Up for Rapid Expansion

The global consumer genomics market is set to witness substantial growth, with revenues projected to increase from $2.42 billion in 2022 to $2.90 billion in 2023, propelled by a strong compound annual growth rate (CAGR) of 19.55%. The market is anticipated to continue its upward trajectory and is forecasted to reach $6.00 billion by 2027, with a CAGR of 19.94%.

Key players in the consumer genomics market include 23andMe Inc., Gene By Gene Ltd., Mapmygenome Ltd., Ancestry.com LLC, Color Genomics Inc., Futura Genetics, Pathway Genomics, Helix OpCo LLC, Positive Biosciences Ltd., Veritas Genetics, Illumina Inc., MyHeritage Ltd., Myriad Genetics Inc., Amgen Inc., Diagnomics Inc., Illumina, Inc., MyHeritage Ltd., Positive Biosciences Ltd., Toolbox Genomics, and Xcode Life.

Reasons to Purchase

  • Gain a comprehensive global perspective on the consumer genomics market, covering 50+ geographies.
  • Understand the market’s response to the COVID-19 pandemic.
  • Assess the impact of the RussiaUkraine war on agriculture, energy, and mineral commodity supply.
  • Measure the influence of high global inflation on market growth.
  • Create regional and country strategies based on local data and analysis.
  • Identify promising growth segments for investment.
  • Leverage forecast data and market trends to outperform competitors.
  • Stay informed about customer preferences based on the latest market shares.
  • Benchmark your company’s performance against key competitors.
  • Access data from the report in an Excel dashboard format.

Consumer Genomics Market Overview

Consumer genomics focuses on providing genetic information directly to consumers through commercial genetic testing services. These services utilize DNA samples provided by individuals to generate reports offering insights into genetic predispositions to traits, diseases, or conditions.

Key product categories in consumer genomics include consumables, systems and software, and other products. Consumables comprise products and materials used in genetic testing, such as collection kits, reagents, and laboratory supplies. Technologies employed include polymerase chain reaction (PCR), sequencing, microarray, nucleic acid extraction and purification. Consumer genomics applications span genetic relatedness, diagnostics, lifestyles, ancestry, wellness and nutrition, reproductive health, personalized medicine and pharmacogenetic testing, sports nutrition and health, among others.

Key Market Trends

Technological advancements are a prominent trend in the consumer genomics market, with leading companies focusing on innovation to enhance their capabilities and maintain a competitive edge.

Recent Acquisition

In [Month, Year], [Company Name], a US-based genetic testing company, completed the acquisition of [Acquired Company Name] for [Acquisition Amount]. This strategic move aimed to [Briefly explain the purpose and benefits of the acquisition, such as expanding product offerings, entering new markets, or enhancing technological capabilities].

Regional Insights

In 2022, North America emerged as the largest region in the consumer genomics market, while Asia-Pacific is expected to experience the fastest growth during the forecast period. The report encompasses regions including Asia-PacificWestern EuropeEastern EuropeNorth AmericaSouth America, and the Middle East and Africa.

Growing Applications of DTC Genomics

The increasing applications of Direct-to-Consumer (DTC) genomics in diagnostics, genetic relatedness, sports nutrition, personalized medicines, and other fields are expected to drive the growth of the consumer genomics market. DTC genomics test kits enable individuals to gain insights into their genetic makeup and health risks from the comfort of their homes. For instance, prenatal paternity genomics testing witnessed a 47.0% surge in demand in 2021 compared to pre-pandemic levels, highlighting the growing adoption of DTC genomics in diagnostics.

Key Topics Covered:

1. Executive Summary

2. Consumer Genomics Market Characteristics

3. Consumer Genomics Market Trends And Strategies

4. Consumer Genomics Market – Macro Economic Scenario
4.1. COVID-19 Impact On Consumer Genomics Market
4.2. Ukraine-Russia War Impact On Consumer Genomics Market
4.3. Impact Of High Inflation On Consumer Genomics Market

5. Consumer Genomics Market Size And Growth
5.1. Global Consumer Genomics Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Consumer Genomics Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Consumer Genomics Market Segmentation
6.1. Global Consumer Genomics Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • Consumables
  • Systems And Software
  • Other Products

6.2. Global Consumer Genomics Market, Segmentation By Technology, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • Polymerase Chain Reaction (PCR)
  • Sequencing
  • Microarray
  • Nucleic Acid Extraction And Purification

6.3. Global Consumer Genomics Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • Genetic Relatedness
  • Diagnostics
  • Lifestyle
  • Ancestry
  • Wellness And Nutrition
  • Reproductive Health
  • Personalized Medicine And Pharmacogenetic Testing
  • Sports Nutrition And Health
  • Other Applications

7. Consumer Genomics Market Regional And Country Analysis
7.1. Global Consumer Genomics Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Consumer Genomics Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”